Regeneron Pharmaceuticals, Inc. (REGN) $664.52
Regeneron is charging back toward its 200-day moving average, but a flashing RSI warning suggests the current sprint may be running out of oxygen.
52-wk High $821.11
📌 Investment Snapshot
- Trading at 16.3x P/E, a significant discount to historical 5-year averages.
- Latest Q1 Revenue of $3.60B with EPS of $6.75 showing stable margins.
- Technical Confluence Score of 100/100 confirms strong trend alignment.
- Wall Street consensus remains bullish with a $822.48 mean price target.
The stock has reclaimed its 50-day SMA following a 10.4% monthly rally. However, the RSI has pierced the 70 level, signaling that the immediate move is overextended.
| 📍 Entry Zone | $637 or below | 🛑 Stop-Loss | $598 |
| 📋 Adjust If | RSI cools below 50 while price holds above the SMA50. | ||
The Investment Case — Why Now?
Regeneron has spent the last 90 days recovering from a sharp drawdown that saw shares bottom near $541. The recent momentum stems from renewed confidence in the Eylea HD franchise and a robust pipeline that continues to offset legacy patent concerns. Institutional accumulation is evident, with Blackrock and Vanguard maintaining massive core positions despite the volatility.
The primary risk remains the 11.1% three-month decline which has left a significant supply of ‘trapped’ longs near the $750 Volume Profile Point of Control. If the 10-year Treasury yield stays elevated at 4.55%, high-growth biotech valuations will face continued pressure on discounted cash flow models. Can Regeneron’s high-dose Eylea maintain its 45%+ market share against intensifying biosimilar competition this year?
🤔 Can Regeneron’s high-dose Eylea maintain its 45%+ market share against intensifying biosimilar competition this year?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Dividend Yield | 0.57% |
| Short Interest | 3.5% |
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $601.22
The price is currently battling the upper Bollinger Band at $676, a level that has historically triggered mean reversion. While the SMA50 at $648.85 has turned upward, the SMA200 at $700.29 looms as a formidable overhead resistance. This gap between the moving averages suggests a period of consolidation is likely before a breakout attempt.
The RSI at 72.3 screams caution for new entries, as it marks the highest reading in over six months. Conversely, the MACD has just completed a bullish crossover with a strong 6.29 spread, indicating that the underlying trend is shifting from bearish to neutral-bullish. The ADX at 33.8 confirms this trend has significant strength behind it.
Anchored VWAP from the July 2025 peak sits exactly at $664.29, creating a ‘battleground’ price where bulls and bears are currently deadlocked. Price action is hovering right on this line, suggesting the next 48 hours will determine the medium-term direction. A failure to hold this level would likely send shares back to the $632 bullish FVG zone.
Volume Profile shows a massive ‘liquidity gap’ between $670 and $750, meaning if REGN clears $675, it could move very quickly toward the POC. However, the volume ratio of 0.57x indicates this recent rally is occurring on thin participation. We need to see a high-volume ‘conviction day’ to validate the move toward $700.
Historically, when REGN hits an RSI above 70 while trading below its SMA200, it tends to pull back 4-6% to retest shorter-term support. Three unfilled bullish Fair Value Gaps (FVGs) remain below current price, acting like magnets for a potential retracement. Patient traders should look for the $632-$637 window to initiate or add to positions.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| REGN | Regeneron Pharmaceuticals | 16.3x |
| VRTX | Vertex Pharmaceuticals | 28.4x |
| AMGN | Amgen Inc. | 15.1x |
| GILD | Gilead Sciences | 12.8x |
| SPY | S&P 500 Avg | 21.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $3.60B | $6.75 | -2% |
| Q4 2025 | $3.88B | $7.78 | +5% |
| Q3 2025 | $3.75B | $13.62 | +12% |
| Q2 2025 | $3.68B | $12.81 | +10% |
Regeneron generated $0.8B in Free Cash Flow last quarter, which was immediately deployed into $0.9B of share buybacks, signaling management’s belief in undervaluation.
Revenue has stabilized in the $3.6B-$3.8B range, though EPS has shown volatility due to R&D timing. The market is currently pricing in a transition year as the company shifts focus to its oncology pipeline and Dupixent expansions.
🚀 Growth Drivers — What Moves the Stock
- Dupixent Expansion 🟢 Upside Surprise — Continued label expansions in COPD and pediatric markets provide a multi-year revenue runway.
- Eylea HD Conversion 🟡 Priced In — Successful migration of patients to the high-dose formulation is protecting the franchise from biosimilar erosion.
- Oncology Pipeline 🟢 Upside Surprise — Early-stage bispecific antibodies could diversify revenue away from ophthalmology by 2027.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 8,947 |
| Vanguard Capital Management | 6,654 |
| Dodge & Cox Inc. | 4,458 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| RYAN ARTHUR F. | Director | 2026-07-02 | Purchase | 200 |
| PITOFSKY JASON | Officer | 2026-02-09 | Sale | 2036 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 3.5% | 3.2 |
⚠ Key Risk Factors
~$1.2B impact
~$50/share impact
🤔 Would you prioritize a low P/E ratio or high revenue growth in this volatile 4.5% yield environment?
🎯 Guidance & Wall Street View
Management expects full-year R&D expenses to remain elevated as they accelerate the immunology pipeline.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $1000.00 | $822.48 | $641.00 | 28 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Piper Sandler | Overweight | $850 | 2026-07-09 | Maintained |
| Benchmark | Buy | $840 | 2026-07-07 | Upgrade |
Analysts are overwhelmingly bullish, seeing the current price as a significant discount to the intrinsic value of the Dupixent/Eylea duopoly.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Dupixent COPD approval exceeds market share expectations.
- Aggressive buybacks continue to reduce float and boost EPS.
📊 Base Case
Eylea HD maintains market dominance while pipeline assets mature steadily.
🐻 Bear Case
- Biosimilar pricing war accelerates revenue decline in legacy Eylea.
- Macro headwinds force a sector-wide biotech de-rating.
🎯 Investor Action Plan — By Profile
The RSI at 72.3 is a clear ‘do not chase’ signal. Wait for a pullback to the $637 level, which aligns with the July 2nd FVG and the SMA50, to manage risk-reward effectively.
If you are already in, stay the course but tighten stops to $610. The Technical Confluence Score of 100 suggests the trend is your friend, but the $700 SMA200 will be a major hurdle.
At 16.3x earnings, you are paying a fair price for a cash-flow machine. Accumulate on any dips toward $600 to capitalize on the 23% upside to consensus targets.
❓ Investor FAQ — People Also Ask
Q: Is Regeneron’s dividend sustainable?
Yes, with a payout ratio well below 10% and $0.8B in quarterly free cash flow, the 0.57% yield is exceptionally safe.
Q: What is the biggest technical hurdle for REGN?
The SMA200 at $700.29 is the primary resistance; the stock has traded below this level for months, and a clean break above it is required for a new bull market.
Q: Why is the RSI so high if the price is down 19% from its peak?
RSI measures the speed and change of recent price movements; the 10.4% gain in just 30 days has triggered the overbought reading despite the long-term decline.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes and does not constitute financial advice. Biotech stocks carry high clinical and regulatory risks.
All active positions and their real-time performance are tracked on our Investment Log.
#REGN #Biotech #StockMarket #Investing #Healthcare #WallStreet #TechnicalAnalysis